

Supplementary Online Content

Farolfi A, Casadei C, Scarpi E, et al. Bevacizumab and platinum choice in pembrolizumab-treated advanced cervical cancer. *JAMA Netw Open*. 2026;9(7):e2623166. doi:10.1001/jamanetworkopen.2026.23166

eTable 1. Cox Proportional Hazards Regression Analysis of Mortality Risk: Cisplatin vs Carboplatin

eTable 2. Baseline Characteristics of the Post Hoc Rematched Bevacizumab Cohort With Prior Chemoradiotherapy Included as a Mandatory Balanced Covariate

eTable 3. Cox Proportional Hazards Regression Analysis of Mortality Risk: Bevacizumab vs No Bevacizumab

eFigure 1. Patient Flow Chart

eFigure 2. Propensity Score Density Function Before and After Matching

eFigure 3. Overall Survival by Choice of Platinum Agent (Cisplatin vs Carboplatin)

eFigure 4. Adverse Events of Special Interest by Treatment Choice

eFigure 5. Propensity Score Density Function Before and After Matching

eFigure 6. Overall Survival by Bevacizumab Use

eFigure 7. Overall Survival by Bevacizumab Use With Previous Chemoradiotherapy as Matching Factor

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Cox Proportional Hazards Regression Analysis of Mortality Risk: Cisplatin vs Carboplatin

Cox Model Results						
Covariate	HR	Coefficient	SE	z	P	95% CI
Cisplatin vs carboplatin	0.95	-0.05	0.08	-0.63	0.52	(0.81, 1.12)
Age at Index	1.00	-0.002	0.003	-0.72	0.47	(0.99, 1.00)
Nicotine dependence	1.35	0.30	0.10	3.01	0.003	(1.11, 1.64)
cisplatin	1.08	0.078	0.08	0.91	0.36	(0.92, 1.27)
Personal history of irradiation	1.26	0.23	0.09	2.42	0.02	(1.05, 1.52)
Asian	1.14	0.13	0.15	0.90	0.37	(0.85, 1.53)
Black or African American	1.49	0.40	0.15	2.69	0.007	(1.11, 1.98)
White	1.39	0.33	0.10	3.27	0.001	(1.14, 1.40)

Abbreviations: CI, confidence interval; HR, hazard ratio; SE, standard error

eTable 2. Baseline Characteristics of the Post Hoc Rematched Bevacizumab Cohort With Prior Chemoradiotherapy Included as a Mandatory Balanced Covariate

Characteristic	Before PSM			After PSM		
	Bev (%) N = 981	NO Bev (%) N = 793	Sdiff	Bev (%) N = 537	NO Bev (%) N = 537	Sdiff
MEAN AGE	52.6 +/- 13.3	58.5 +/- 13.3	0.48	53.8 +/- 13.3	54.1 +/- 13.0	0.02
RACE						
Caucasian	550 (56.1)	451 (56.9)	0.02	289 (53.8)	303 (56.4)	0.05
Black/African American	111 (11.3)	112 (14.1)	0.08	65 (12.1)	60 (11.2)	0.03
Asian	96 (9.8)	62 (7.8)	0.07	50 (9.3)	48 (8.9)	0.01
Others/Unknown	224 (22.8)	168 (21.2)	0.05	133 (24.8)	126 (23.5)	0.03
Smokers	146 (14.9)	80 (10.1)	0.15	58 (10.8)	64 (11.9)	0.04
PRIOR TREATMENTS						
Prior CRT	401 (40.9)	127 (16.0)	0.57	124 (23.1)	126 (23.5)	0.01
BMI						
<18.5 kg/m2	70 (7.2)	23 (2.9)	0.20	23 (4.3)	22 (4.1)	0.01
18.5-25 kg/m2	271 (27.6)	258 (32.5)	0.23	208 (38.7)	226 (42.1)	0.05
25-30 kg/m2	313 (31.9)	211 (26.6)	0.12	144 (26.8)	139 (25.9)	0.02
>30 kg/m2	327 (33.3)	301 (38.0)	0.10	162 (30.2)	150 (27.9)	0.05

Abbreviations: aCC, advanced cervical cancer; bev, bevacizumab; BMI, body mass index; CRT, chemo-radiotherapy; Sdiff, standard difference.


eTable 3. Cox Proportional Hazards Regression Analysis of Mortality Risk: Bevacizumab vs No Bevacizumab

Cox Model Results						
Covariate	HR	Coefficient	SE	z	P	95% CI
Bev vs no bev	0.87	-0.14	0.09	-1.53	0.13	(0.73, 1.04)
Age at Index	1.00	0.00	0.003	0.12	0.90	(0.99, 1.01)
Nicotine dependence	1.09	0.09	0.12	0.75	0.46	(0.87, 1.37)
cisplatin	1.14	0.13	0.10	1.40	0.16	(0.95, 1.38)
Personal history of irradiation	1.09	0.09	0.11	0.80	0.43	(0.88, 1.34)
Asian	1.05	0.05	0.18	0.25	0.80	(0.73, 1.50)
Black or African American	1.60	0.47	0.15	3.06	0.002	(1.18, 2.16)
White	1.33	0.28	0.12	2.43	0.015	(1.06, 1.66)

Abbreviations: CI, confidence interval; HR, hazard ratio; SE, standard error


eFigures

eFigure 1. Patient Flow Chart




eFigure 2. Propensity Score Density Function Before and After Matching


(cisplatin - purple, carboplatin - green)



eFigure 3. Overall Survival by Choice of Platinum Agent (Cisplatin vs Carboplatin)




eFigure 4. Adverse Events of Special Interest by Treatment Choice




eFigure 5. Propensity Score Density Function Before and After Matching
(bevacizumab - purple, no bevacizumab - green)


Before Matching



After Matching



eFigure 6. Overall Survival by Bevacizumab Use



eFigure 7. Overall Survival by Bevacizumab Use With Previous Chemoradiotherapy as Matching Factor

